Inhibrx Biosciences, Inc. Common Stock (INBX) is a publicly traded Healthcare sector company. As of May 21, 2026, INBX trades at $106.96 with a market cap of $1.55B and a P/E ratio of -13.02. INBX moved +0.42% today. Year to date, INBX is +43.09%; over the trailing twelve months it is +741.70%. Its 52-week range spans $10.81 to $155.29. Analyst consensus is buy with an average price target of $277.50. Rallies surfaces INBX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Inhibrx Biosciences, Inc. Common Stock (INBX) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. INBX moved +0.42% today. Analyst consensus is buy.
| Metric | Value |
|---|---|
| Price | $106.96 |
| Market Cap | $1.55B |
| P/E Ratio | -13.02 |
| EPS | $-8.39 |
| Dividend Yield | 0.00% |
| 52-Week High | $155.29 |
| 52-Week Low | $10.81 |
| Volume | 3 |
| Avg Volume | 0 |
| Revenue (TTM) | $1.30M |
| Net Income | $-130.19M |
| Gross Margin | 0.00% |
2 analysts cover INBX: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $277.50.